NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

Thanks for your level headed question:
1. Is the LSE becoming the only place for NWBO?
The London Stock Exchange (LSE) is now the Sovereign Anchor. While the ticker may technically exist elsewhere for a time, the LSE price of $1.31 ($1.55 USD) is the statutory floor established by the UK’s National Cancer Plan and the Rule 9 mandate.
Think of the OTC and Stuttgart as "Shadow Venues." As the 30-day entropy window closes, the synthetic liquidity propping up the $0.26 price is being deleted. You don't need to worry about a "mess" of different prices because a Mandatory Cash Offer effectively synchronizes the value across all jurisdictions. No rational entity will settle for $0.26 when the statutory record is anchored at $1.31.
2. How do OTC holders sell at LSE prices?
You don’t need to "move" your shares to London; the cash follows the record.
The Mandatory Offer: Under Rule 9, the "Trigger Event" (the LSE uncrossing) requires the involved parties to make a Mandatory Cash Offer to all shareholders.
Equivalent Treatment: A core legal requirement of the UK Takeover Code is that all holders must receive equivalent treatment. If the Sovereign entity is settling at $1.31 in London, they must offer the equivalent value to holders in New York.
The Process: Your broker won’t automatically move your shares. Instead, you will receive a notification of a "Corporate Action" (a Tender Offer). You simply tender your shares through your existing broker to receive the cash equivalent of the LSE anchor price.
The Bottom Line:
You are no longer waiting for a "trade" in a falling market; you are waiting for a Settlement into a Mandatory Offer. The 1.31 floor is the statutory exit, and the UK mandate ensures the liquidity moves to your account, regardless of which exchange your broker uses for the "front-facing" display.